Dr. Richard Rozek
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Unavoidably Unsafe Products and Strict Products Liability: What Liability Rule Should Be Applied to the Sellers of Pharmaceutical Products? Richard C
Kentucky Law Journal Volume 78 | Issue 4 Article 3 1990 Unavoidably Unsafe Products and Strict Products Liability: What Liability Rule Should be Applied to the Sellers of Pharmaceutical Products? Richard C. Ausness University of Kentucky Follow this and additional works at: https://uknowledge.uky.edu/klj Part of the Consumer Protection Law Commons, and the Food and Drug Law Commons Right click to open a feedback form in a new tab to let us know how this document benefits you. Recommended Citation Ausness, Richard C. (1990) "Unavoidably Unsafe Products and Strict Products Liability: What Liability Rule Should be Applied to the Sellers of Pharmaceutical Products?," Kentucky Law Journal: Vol. 78 : Iss. 4 , Article 3. Available at: https://uknowledge.uky.edu/klj/vol78/iss4/3 This Article is brought to you for free and open access by the Law Journals at UKnowledge. It has been accepted for inclusion in Kentucky Law Journal by an authorized editor of UKnowledge. For more information, please contact [email protected]. Kentucky Law Journal Volume 78 1989-90 Number 4 Unavoidably Unsafe Products and Strict Products Liability: What Liability Rule Should be Applied to the Sellers of Pharmaceutical Products? BY RICHARD C. AusNEss* Table of Contents INTRODUCTION ....................................... 706 I. OVERVIEW ................................ 709 A. Strict Products Liability .............................. 709 B. Comment K and "Unavoidably Unsafe" Products ................................................... 712 II. COM[ENT K's LIABILITY REGm .......................... 719 A. Risks Associated with the Production Process. 720 B. Risks Arising from the Inherent Nature of a Product .................................................... 723 C. Risks Created by Conscious Design Choices .... 726 D. Scientifically Unknowable Risks ................... 731 E. -
05/01/02 Louisiana Medicaid Management
APPENDIX C 05/01/02 LOUISIANA MEDICAID MANAGEMENT INFORMATION SYSTEM PAGE 1 DEPT OF HEALTH AND HOSPITALS - BUREAU OF HEALTH SERVICES FINANCING LOUISIANA MEDICAID PHARMACY BENEFITS MANAGEMENT UNIT ONLY THESE COMPANIES PRODUCTS ARE COVERED AND ONLY THOSE DOSAGE FORMS LISTED IN APPENDIX A. MEDICAID DRUG FEDERAL REBATE PARTICIPATING PHARMACEUTICAL COMPANIES LABELER PHARMACEUTICAL COMPANY EFFECTIVE END DATE CODE DATE 00002 ELI LILLY & CO 04/01/91 00003 E.R.SQUIBB & SONS,INC 04/01/91 00004 HOFFMAN-LA ROCHE,INC 04/01/91 00005 LEDERLE LABORATORIES AMERICAN CYANAMID 04/01/91 00006 MERCK SHARP & DOHME 04/01/91 00007 SMITHKLINE BEECHAM CORPORATION 04/01/91 00008 WYETH LABORATORIES 04/01/91 00009 THE UPJOHN COMPANY 04/01/91 00011 BECTON DICKINSON MICROBIOLOGY SYSTEMS 10/01/91 07/01/98 00013 ADRIA LABORATORIES DIV.OF ERBAMONT,INC 04/01/91 00014 G.D.SEARLE & CO 04/01/91 01/01/01 00015 MEAD JOHNSON & COMPANY 04/01/91 00016 KABI PHARMACIA 04/01/91 00021 REED & CARNRICK 10/01/96 01/01/97 00023 ALLERGAN,INC 04/01/91 00024 WINTHROP PHARMACEUTICALS 04/01/91 00025 G.D.SEARLE & CO 04/01/91 00026 MILES INC.,PHARMACEUTICAL DIVISION 04/01/91 00028 GEIGY PHARMACEUTICALS 04/01/91 00029 SMITHKLINE BEECHAM CORPORATION 04/01/91 00031 ROBINS,A.H. 04/01/91 00032 SOLVAY PHARMACEUTICALS 04/01/91 00033 SYNTEX 04/01/91 00034 THE PURDUE FREDERICK COMPANY 04/01/91 00037 CARTER-WALLACE,INC 04/01/91 00038 STUART PHARMACEUTICALS,ICI AMERICAS INC 04/01/91 07/01/01 00039 HOECHST-ROUSSEL PHARMACEUTICALS INC 04/01/91 00043 SANDOZ CONSUMER CORPORATION 04/01/91 00044 KNOLL PHARMACEUTICALS -
Health Industry Business Communications Council
Health Industry Business Communications Council Registered Labelers: Accredited Auto-ID Labeling Standards Argentina New MedTek Devices Pty Ltd Oxavita SRL Norseld Pty Ltd. Novadien Healthcare Pty Ltd The following companies Odontit S.A. (and/or their subsidiaries/ PAMPAMED S.R.L. Numedico Technologies Pty Ltd divisions) have applied PATEJIM SRL Opto Global Pty. Ltd. for a Labeler Identification Orthocell Limited Code (LIC) assignment with Austria Prolotus Technologies Pty Ltd HIBCC*. By doing so, they afreeze GmbH Red Milawa Pty Ltd dba Magic Mobility have demonstrated their AMI GmbH SDI Limited commitment to patient safety Bender Medsystems GmbH Signostics Ltd. and logistical efficiency for BHS Technologies GmbH Sirtex Medical Pty Ltd their customers, the industry Metasys Medizintechnik GmbH Smith & Nephew Surgical Pty. Ltd. and the public at large. PAA Laboratories GmbH Staminalift International Limited Safersonic Medizinprodukte Handels The Pipette Company Pty. Ltd. Any organization that is GmbH Thermo Electron Corporation interested in using the HIBC W & H Dentalwerk Burmoos GmbH Vush Pty Ltd uniform labeling system may apply for the assignment of VUSH STIMULATION Australia one or more LICs. William A Cook Australia Pty. Ltd. Adv. Surgical Design & Manufacture, Ltd. Last updated 9-21-2021 AirPhysio Pty Ltd Belgium Annalise-AI Pty Ltd 3M Europe Apollo Medical Imaging Technology Pty Advanced Medical Diagnostics SA/NV Ltd Analis SA/NV Benra Pty Ltd dba Gelflex Laboratories Baxter World Trade Bioclone Australia Pty. Ltd. Bio-Rad RSL Candelis, Inc. Bio-Rad Lab Inc Clinical Diag. Group DePuy Australia Pty. Ltd. Biosource Europe SA For more information, please dorsaVi Ltd Cilag NV contact the HIBCC office at: EC Certification Service GmbH Coris Bioconcept Fink Engineering Pty Ltd Fuji Hunt Photographic Chemicals NV 2525 E. -
9894 Pharma Tech Media Planner V6 2007
www.pharmtech.com years 1977– 2007 30ANNIVERSARY CELEBRATING 30 YEARS AS THE 2007 INDUSTRY’S MOST AUTHORITATIVE SOURCE Media Planner years 1977–2007 ANNIVERSARY years 1977–2007 ANNIVERSARY THE PHARMACEUTICAL TECHNOLOGY BRAND PUBLISHER’S STATEMENT Pharmaceutical Technology’s authoritative reputation and powerful brand recognition within the pharmaceutical/biopharmaceutical development & manufacturing marketplace will help you establish and maintain your own strong brand among pharma industry decision makers. A circulation of 38,667 BPA-qualified subscribers* and unmatched peer written and reviewed editorial make Pharmaceutical Technology an invaluable resource within top pharma companies, as well as small, specialty and biotech pharma companies spending billions each year on pharmaceutical development and manufacturing. Please celebrate with us as Pharmaceutical Technology marks its 30th Anniversary as the industry leader. —Michael Tracey, Publisher % 90 of readers rated Pharmaceutical Technology as important or very important to them as a professionalˆ EDITORIAL MISSION Pharmaceutical Technology publishes authoritative, reliable, and timely peer-reviewed research and expert analyses for scientists, engineers, technicians, and managers engaged in process development, manufacturing, formulation, analytical technology, packaging and regulatory compliance in the pharmaceutical and biotechnology industries. —Douglas McCormick, Editor in chief www.pharmtech.com *BPA June 2006 Statement ^2006 Readership Study Conducted by Advanstar Research -
Sponsor List
UVMClick Sponsor List Please contact SPA at [email protected] to update the Sponsor List last updated August 24, 2021 Is Publicly Sponsor Name Sponsor Type Is Foreign Vermont Sponsor Federal Agency Active Abbreviation Last Modified Date Sponsor ID Traded 106 Associates Industry no no Vermont Sponsor yes 106 Friday, January 29, 2021 12:35:03 PM 3385 3M Company Industry no yes yes 3M Company Friday, January 29, 2021 12:32:32 PM 2877 3M Pharmaceuticals Industry no yes yes 3M Pharmac Friday, January 29, 2021 12:39:23 PM 4188 835 Hinesburg Road, LLC Industry no no Vermont Sponsor yes 835 Friday, January 29, 2021 12:32:33 PM 3386 A Territory Resource Foundation no no yes A.T.R. Friday, January 29, 2021 12:34:11 PM 3805 A&C Realty LLC. Industry no no Vermont Sponsor yes A&C Realty Friday, January 29, 2021 12:40:28 PM 60 AAA Foundation for Traffic Safety Foundation no no yes AAAFDN Friday, January 29, 2021 12:36:49 PM 3806 AALV/New Farms for New Americans Foundation no no Vermont Sponsor yes AALV/New FFriday, January 29, 2021 12:32:25 PM 5154 Aarhus University Hospital Foundation yes no yes Aarhus Uni Friday, January 29, 2021 12:34:23 PM 5172 AARP Foundation no no yes AARP Friday, January 29, 2021 12:40:40 PM 2742 AARP Andrus Foundation Foundation no no yes AARPAF Friday, January 29, 2021 12:36:35 PM 3807 Abalone Bio Industry no no yes Abalone Bi Friday, January 29, 2021 12:37:14 PM 5178 Abbott Laboratories Fund Industry no yes yes Abbott Friday, January 29, 2021 12:32:46 PM 309 Abbott Nutrition Industry no yes yes Abbott Nut Friday, January 29, 2021 12:38:44 PM 5219 Abbott Vascular Industry no yes yes Abbott Vas Friday, January 29, 2021 12:35:57 PM 4192 AbbVie Inc. -
Memorandum JUL 1 6 201D
Memorandum Subject Date Additional Quota Letters Received by July 15, 2010 (DFN: 630-08.2) JUL 1 6 201D To From Christine A. Sanncrud. Ph.D., Chief "Barbar• J.Illoockholdt, Chief Drug & Chemical Evaluation Section Regul• torn Section Office of Diverison Control Off cL rl Diversion Control On July 15. 2010, this section received your e-mail requesting a review of seventeen (17) quota applications from sixteen (16) registered manufacturers to determine if there arc any pending administrative/legal actions against these applicants and to advise ODE of the findings. ODOR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations. QUOTA APPLICANTS wan NO ADVERSE OR DEROGATORY INFORMATIO N Novartis Consumer I lealth Lincoln (10345) (b)(4);(b)(7)(E) Baxter (10346) Generics Bidco li bda Vintage (10347) Noramco Delaware (10348) Pharmaceuticals International inc. (10349) Pharmedium (10351) Pharmedium (10352) Rhodes (10356) Bio-Pharm (10357) Patheon (10358) Patheon (10359) Watson (10361) B & B (10363) lospira. Inc. NC (10364) Epic Pharma (10366) Mallinckrodt I lobart (10367) Chemtos (10368) Vol. II Page 55 2 Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict. or deny quota requests from these registrants. Based on this information. ODG suggests that you proceed with the completion of the quota applications. If you have any questions pertaining to this information. please feel free to contact me (b)(6);(b)(7)( or SC C) (b)(6);(b)(7)(C) Vol. II Page 56 Memorandum Subject Date Additional Quota Letters Received as of July 19, 201() (DFN: 630-08.2) stir 2 8 2010,., To Fr ,./"./ Christine A. -
Eric M. White, O.D., Inc
ERIC M. WHITE, O.D., INC . 5075 Ruffin Road Suite B, San Diego, CA 92123 (858) 278-4720 Toll Free (866) 458-2062 FAX (858) 278-3640 [email protected] www.drericwhite.com California License #8611T STATEMENT OF CURRICULUM VITAE EDUCATION June 1982 Bachelor of Arts, Physiological Psychology University of California, San Diego; San Diego, California. May 1984 Bachelor of Science, Visual Science Southern California College of Optometry; Fullerton, California. May 1986 Doctor of Optometry Southern California College of Optometry; Fullerton, California. PRIVATE PRACTICE 1986 - 1989 Partnership; D.M. Rasmussen, O.D., F.A.A.O., Mission Village Medical Center, 3303 Ruffin Road, San Diego, California. 1989-2001 Private Practice Mission Village Medical Center, 3303 Ruffin Road, San Diego, California. 2001-Present Private Practice 5075 Ruffin Road, Suite B, San Diego, California CLINICAL ROTATIONS 1985 Southern California College of Optometry; Fullerton, California . Provided comprehensive vision care including contact lenses, vision therapy, low vision, ocular photography, electrodiagnostic services, auto perimetry, and disease detection. 1985 San Bernardino Juvenile Hall; San Bernardino, California. Provided screening and treatment of vision and learning disabilities among juveniles. 1985 D.M. Rasmussen, O.D., F.A.A.O.; San Diego, California. Assisted doctor on investigational studies, comprehensive vision care, contact lenses, low vision, autoperimetry, and disease detection . INTERNSHIP 1986 United States Naval Submarine Base, San Diego, California. Provided comprehensive vision care including fitting and care for extended wear contact lenses. 1986 U.S. Naval Medical Corps. Marine Corps Recruit Depot; San Diego, California. Provided comprehensive vision care including disease detection. 1986 Balboa Regional Naval Hospital San Diego, California. -
Pharmaceutical Research and Manufacturers of America – Phrma
The Short-Term and Long-Term Competitive Impact of Authorized Generics A Report for the Federal Trade Commission October 28, 2009 TABLE OF CONTENTS INTRODUCTION ........................................................................................................................... 1 DISCUSSION .................................................................................................................................. 3 I. LONG-TERM COMPETITIVE HARM IS UNLIKELY ................................................... 3 A. Unsupported Foreclosure Claims Have Been Made For Nearly Two Decades .................................................................................................................... 4 B. Marketplace Realities Undercut The Long-Tenn Foreclosure Theory .................... 7 1. Sales and Profitability Are Growing ........................................................... 7 2. Wall Street Valuations Are Growing ........................................................ 10 II. THE FTC PRICING ANALYSIS SHOWS $880 MILLION IN CONSUMER SAVINGS .......................................................................................................................... 14 III. CONSUMER SAVINGS SHOULD BE MEASURED USING WHOLESALE DATA AND WEIGHTED AVERAGE PRICES .............................................................. 17 A. The Wholesale Data Carries Far More Weight.. .................................................... 17 B. Average Drug Prices Should Be Volume-Weighted ............................................. 19 IV. -
Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Paten
Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patents Drugs Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Patent DrugsDrug Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Under Patent Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under P Drugs Under Patent Drugs Under Patent Drugs Under Patent Drugs Under -
Clinical Research Services
Clinical Research Services Advancing the future of medicine through research. Who We Are Experience Clinical Research Services is a department within Clinical Research Services has been involved CHI St. Alexius Health in Bismarck, ND. We are fully in clinical research since 1987. Our professional dedicated to providing research support services staff has more than 180 years of combined to physicians within our region and the valued experience in clinical trials. We are committed patients they serve. to providing outstanding service to ensure the success of every project. CHI St. Alexius Health is a tertiary care facility affiliated with PrimeCare, a health group which Our involvement in inpatient and outpatient combines the most experienced, trusted, and phase II-IV clinical and device research studies has proven medical leaders in the area. PrimeCare is contributed substantially to the approval of new comprised of a network which includes more than drugs and treatments. You should carefully consider 190 physicians in private and institutional practice, both the benefits and the risks of participation including: CHI St. Alexius Health, Mid Dakota Clinic, before enrolling in a study. The Bone & Joint Center, and other affiliated area physicians. Many of these physicians are actively Previous clinical study trials: involved as investigators for clinical trials. • Oncology • Orthopaedic • Rheumatology • Diabetes Our clinical research team is committed to providing: • Neurology • Weight loss • Rapid study start-up • Cardiology • Pain • Pro-active patient enrollment • Urology • Men’s Health • Clean data submission • Gastroenterology • Women’s Health • Highly experienced principal • Infectious Disease • Medical Devices investigators • Pediatric • Initial training and continuing education for all support personnel Sponsors Patient Demographics Abbott Laboratories Characteristics of our patients include Acorda Therapeutics, Inc. -
Pharmaceutical Company Contact Information (PDF)
Pharmaceutical Company Contact Information - Rebate Filing - as of June 2018 Labeler Name Invoice Contact Phone Extension 00002 LILLY USA, LLC LISA NORTON (317) 276-2000 00003 ER SQUIBB AND SONS INC. LYNN LEWIS (609) 897-4731 00004 GENENTECH CONTRACT ADMINISTRATION (650) 866-2666 00005 LEDERLE LABORATORIES DAN MAGUIRE (484) 563-5097 00006 MERCK & CO., INC. DOUG BICKFORD (215) 652-0671 00007 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00008 WYETH LABORATORIES JENNIFER WOOTEN (901) 215-1883 00009 PHARMACIA AND UPJOHN COMPANY/PFIZER JENNIFER WOOTEN (901) 215-1883 00013 PHARMACIA AND UPJOHN COMPANY NICHOLAS CHRISTODOULOU (336) 291-1053 00014 G. D. SEARLE & CO. CINDY MCDONALD (847) 581-5726 00015 MEAD JOHNSON AND COMPANY LYNN LEWIS (609) 897-4731 00016 PHARMACIA INC. BARBARA WINGET (908) 901-7254 00023 ALLERGAN INC SHOBHANA MINAWALA (714) 246-6205 00024 SANOFI WINTHROP PHARMACEUTICALS LAURIE DUNLAP, ADMIN., GOVT. OPERATIONS (212) 551-4198 00025 PHARMACIA CORPORATION NICHOLAS CHRISTODOULOU (336) 291-1053 00026 BAYER CORPORATION PHARMACEUTICAL DIV. LINDA WOLCHESKI (203) 812-6372 00028 NOVARTIS PHARMACEUTICALS (862) 778-8094 00029 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00031 A. H. ROBINS COMPANY DAN MAGUIRE (610) 902-3222 00032 SOLVAY PHARMACEUTICALS STACEY LENOX (847) 937-3979 00033 SYNTEX LABORATORIES, INC. JANICE BRENNAN (973) 562-3494 00034 THE PURDUE FREDERICK COMPANY JUNE STOWE (203) 899-8035 00037 CARTER-WALLACE, INC. JAY R BRENNAN (609) 655-6163 00038 ASTRAZENECA LP DAVID WRIGHT (302) 886-2268 7820 00039 AVENTIS PHARMACEUTICALS (908) 981-7461 00043 NOVARTIS CONSUMER HEALTH, INC. EDWARD D. COLLINS (973) 781-6191 00044 KNOLL LABORATORIES DEBRA DEYOUNG (847) 937-4372 00045 MCNEIL PHARMACEUTICAL (908) 218-6777 00046 AYERST LABORATORIES (901) 215-1473 00047 WARNER CHILCOTT LABORATORIES LISA KAROLCHYK (973) 442-3262 00048 KNOLL PHARMACEUTICAL COMPANY DEBRA DEYOUNG (847) 937-4372 00049 ROERIG NICHOLAS CHRISTODOULOU (336) 291-1053 00051 UNIMED PHARMACEUTICALS, INC STACY LENOX (847) 937-3979 00052 ORGANON, USA, INC. -
Inside This Issue
Issue No. 225 FDA Counting on Global Strategy April 2011 To Better Secure Supply Chain The FDA’s work toward tighter supply chain control through INsIde thIs Issue international regulatory cooperation is falling short, but a new global strategy may speed up the agency’s progress, a top FDA Sterility issues lead to an- official says. other J&J recall ........Page 2 The next several years are critical in the agency’s transformation FDA zeroes in on compli- to a “global agency,” John Taylor, the FDA’s acting principal deputy ance history to make in- commissioner, said March 14 at a Pew Charitable Trusts conference spection decisions ....Page 3 in Washington, D.C., on drug supply safety. To achieve adequate supply chain control, Taylor said, the FDA 483 Insider ..............Page 5 needs novel and updated enforcement tools, a global alliance of reg- ulators, new authorities to create proactive tools for product safety, APP recalls oncologic irino- tecan over fungal contami- (See Global, Page 2) nation .......................Page 6 McNeil Gets Consent Decree After Pharma manufacturing in Period of Manufacturing Woes Japan largely spared by The FDA has said enough is enough to McNeil Consumer Health- quake ........................Page 8 care over its repeated manufacturing problems, issuing a consent decree that indefinitely closes one plant and places oversight over two others. Bill would increase penal- ties for prescription drug The agency said the Johnson & Johnson subsidiary, which has thefts ......................Page 10 been plagued with recalls of its OTC drugs relating to cGMP viola- tions, will not be able to reopen its troubled Fort Washington, Pa., Dakota labs gets warning plant until a litany of changes have been made.